Asahi Intecc Co ( (AHICF) ) has released its Q1 earnings. Here is a breakdown of the information Asahi Intecc Co presented to its investors.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Asahi Intecc Co., Ltd. is a Japanese company listed on the Tokyo and Nagoya Stock Exchanges, primarily engaged in the medical device industry, known for its innovative technologies and global market presence. The company’s recent financial report for the quarter ending September 30, 2024, shows a steady growth trajectory with net sales reaching 31,184 million yen, marking an 8.6% increase compared to the previous year. This growth is largely attributed to the robust performance of its Medical Division both domestically and internationally.
Key financial metrics indicate a positive performance for Asahi Intecc. Operating profit saw a notable rise of 20.9% year-on-year, totaling 9,726 million yen, and ordinary profit increased by 7.3% to 8,767 million yen. The company’s profit attributable to owners of the parent was reported at 6,784 million yen, an 11.7% rise from the previous year. The Medical Division, a major contributor to the company’s growth, showed strong sales driven by market share expansion and favorable foreign exchange impacts.
The Device Division, however, experienced a decline in net sales by 4.6% year-on-year, primarily due to decreased sales in medical components. Despite this, the division maintained stable sales in industrial components. The company’s overall financial position shows a slight decrease in total assets to 179,238 million yen from the previous fiscal year. This was due mainly to reductions in cash and deposits and accounts receivable, though liabilities also decreased, reflecting improved financial management.
Looking ahead, Asahi Intecc maintains its optimistic financial outlook, expecting continued growth across its divisions. Despite external challenges such as currency fluctuations, the company is focused on executing its strategic plans to enhance corporate value and sustain its growth trajectory in the global medical device market.
